Xilio Therapeutics, Inc. Increase (Decrease) in Deferred Revenue
Xilio Therapeutics, Inc. (XLO) reported Increase (Decrease) in Deferred Revenue of -$25.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-12
- Xilio Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-06-30 was -$12.69M.
- Xilio Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was -$12.65M, a 127.37% decline year-over-year.
- Xilio Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was -$8.69M.
- Xilio Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was -$1.56M.
- Xilio Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2025 was $27.88M, a 14.96% decline from fiscal 2024.
- Xilio Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2024 was $32.78M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$12.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$25.34M 10-Q · filed 2026-08-12 | -$34.03M derived: sum of 3 quarters · filed 2026-08-12 | -$35.59M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$12.65M 10-Q · filed 2026-05-12 | -$21.34M derived: sum of 2 quarters · filed 2026-05-12 | -$22.90M derived: sum of 3 quarters · filed 2026-05-12 | -$30.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$8.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$10.25M derived: sum of 2 quarters · filed 2026-03-23 | -$18.34M derived: sum of 3 quarters · filed 2026-08-12 | $27.88M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$9.65M derived: sum of 2 quarters · filed 2026-08-12 | $36.56M 10-Q · filed 2025-11-13 | $34.84M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$8.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $38.13M 10-Q · filed 2026-08-12 | $36.41M derived: sum of 3 quarters · filed 2026-08-12 | $34.14M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $46.21M 10-Q · filed 2026-05-12 | $44.49M derived: sum of 2 quarters · filed 2026-05-12 | $42.23M derived: sum of 3 quarters · filed 2026-05-12 | $39.87M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$3.99M derived: sum of 2 quarters · filed 2026-03-23 | -$6.34M derived: sum of 3 quarters · filed 2026-03-23 | $32.78M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$2.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$4.62M derived: sum of 2 quarters · filed 2025-11-13 | $34.50M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$2.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $36.77M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $39.12M 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |